Brind.

Researcher Presents Research on Delta Opioid Receptor in Cancer Immunotherapy

1 report, 1 independent Updated 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

TuHURA Biosciences announced that it will present research at the 68th American Society of Hematology Annual Meeting in New Orleans. The research highlights the role of the Delta Opioid Receptor (DOR) in controlling the immunosuppressive capabilities of Myeloid-Derived Suppressor Cells (MDSCs) and other immune cells. Krit Ritthipichai also presented research at the ASH meeting in New Orleans.

From prnewswire.com

Why it matters

Some supportBrind's analysis of the reports

The research suggests that DOR plays a central role in the proliferation and immune suppression capabilities of MDSCs, T regs, and M2 macrophages. These cells are known to cause resistance and failure in cancer immunotherapy when hijacked by cancer.

From prnewswire.com

Who's involved

  • Krit RitthipichaiResearcher who presented findings at the ASH meeting

Who could feel it

Possible knock-on effects

These are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.

  • Krit RitthipichaiSpeculative

    Biotechnology firms developing oncology treatments might see increased investment in drug discovery related to the Delta Opioid Receptor.

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped